March 20, 2019 10:28 AM EDTUpdated May 22, 11:31 AM
R&D
Pharma

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

Amber Tong

The past four years of col­lab­o­rat­ing with NGM Bio has de­liv­ered a late-stage NASH drug for Mer­ck, which paid up $20 mil­lion to li­cense the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times